Histapharma Spółka z Ograniczoną Odpowiedzialnością (KRS 0000729465, NIP 9721289685) is a Polish company, headquartered in Złotniki, Wielkopolskie voivodeship. HISTAPHARMA operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since April 25, 2018. HISTAPHARMA's most recently reported net revenue was 0 PLN for 2025.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Histapharma
Identity
- Name
- Histapharma Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 25, 2018
- Registry status as of
- May 16, 2026
- Latest entry
- May 15, 2026
- Founding act
- 23.04.2018 R.
Articles of association history (2)
- April 23, 2018: 23.04.2018 R.
- April 26, 2018: AKT NOTARIALNY Z DNIA 26.04.2018 R., REP. A NR 1172/2018, ZASTĘPCA NOTARIALNY PIOTR CIENIUCH Z KANCELARII NOTARIALNEJ MAGDALENY WALTER - NOTARIUSZ, PRZY ULICY NIECAŁEJ NR 12/3, 60-805 POZNAŃ, ZMIANA § 9, UCHYLONO DOTYCHCZASOWĄ TREŚĆ UMOWY SPÓŁKI I NADANO JEJ NOWE BRZMIENIE; AKT NOTARIALNY Z DNIA 30.05.2018 R., REP. A NR 1598/2018, ZASTĘPCA NOTARIALNY PIOTR CIENIUCH Z KANCELARII NOTARIALNEJ MAGDALENY WALTER - NOTARIUSZ, PRZY ULICY NIECAŁEJ NR 12/3, 60-805 POZNAŃ, ZMIENIONO PAR. 13 UST. 3.
Activities
Main activity
21.20.ZManufacture of pharmaceutical preparations
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KRZEMOWA, 1, 62-002, ZŁOTNIKI, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃSKI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-86850-83218-TBCVW-37
Risk and payment profile - Histapharma
Credibility rating
55.2 / 100
Average credibility
Insolvency risk
Very low
Elevated threat
Closure risk
20
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/8 yrs
Board changes
0
0/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: C (55/100)
Trend: deteriorating (-8.7 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2025
Current: 100.6 K PLN
Safe: 45.3 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Histapharma
Founded
April 25, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ZŁOTNIKI
WIELKOPOLSKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
20.0 K PLN
400 shares total
Shareholders
3
shareholders
Board
1 person
Filed years
7 years
2018–2025
Registry entries
29
latest: May 15, 2026
Revenue
0 PLN
2025
Net profit
1.8 K PLN
2025
Assets
1.1 M PLN
2025
Equity
192.7 K PLN
2025
EBITDA
N/A
2025
no depreciation data
Valuation
409.3 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Histapharma.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
